VOLUMINA MEDICAL, a spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL) specialized in developing innovative biomaterials announced that it has raised an undisclosed amount in a Series A fund raising. The round involved existing investors and notable new investors, including Clinique La Prairie and Skyviews Life Science Ltd.
At present, around 2 million women are diagnosed with breast cancer each year worldwide, 500’000 of whom are in Europe. These patients increasingly resort to reconstructive surgeries after tumour resection to regain their natural and healthy physical appearance. Unfortunately, today, the available techniques are either too burdensome, induce long-term foreign body reactions, require repeated surgeries or do not bring durable results. In addition, a high number of patients are not eligible for one of these techniques and remain untreated.
To address this significant unmet medical need, Volumina Medical has been working for a number of years on the development of a platform of novel injectable biomaterials to support soft tissue repair. The lead product from this work is AdipearlTM which has gone through extensive pre-clinical studies and is now being tested in patients. First therapeutic target is breast reconstruction following cancer surgery.